Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

First Published Online March 16, 2009
The Oncologist, Vol. 14, No. 3, 240-252, March 2009; doi:10.1634/theoncologist.2008-0165
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0165v1
14/3/240    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smits, E. L.J.M.
Right arrow Articles by Van Tendeloo, V. F.I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smits, E. L.J.M.
Right arrow Articles by Van Tendeloo, V. F.I.

Leukemias

Immunotherapy of Acute Myeloid Leukemia: Current Approaches

Evelien L.J.M. Smitsa, Zwi N. Bernemana,b, Viggo F.I. Van Tendelooa,b

aVaccine & Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium; bCenter for Cellular Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium

Key Words. Myeloid leukemia • Active immunotherapy • Passive immunotherapy

Correspondence: Viggo F.I. Van Tendeloo, VIDI, Laboratory of Experimental Hematology, University of Antwerp (UA), Antwerp University Hospital (UZA), Wilrijkstraat 10, B-2650 Antwerp, Belgium. Telephone: 32-3-8213661; Fax: 32-3-8214456; e-mail: viggo.van.tendeloo{at}uza.be

Received August 1, 2008; accepted for publication February 16, 2009; first published online in THE ONCOLOGIST Express on March 16, 2009.

Disclosures

Evelien L.J.M. Smits: None; Zwi N. Berneman: None; Viggo F.I. Van Tendeloo: None.

Section editors Bob Löwenberg and Joseph G. Jurcic have disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Target audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in leukemias.

Following standard therapy that consists of chemotherapy with or without stem cell transplantation, both relapsed and refractory disease shorten the survival of acute myeloid leukemia (AML) patients. Therefore, additional treatment options are urgently needed, especially to fight residual AML cells. The identification of leukemia-associated antigens and the observation that administration of allogeneic T cells can mediate a graft-versus-leukemia effect paved the way to the development of active and passive immunotherapy strategies, respectively. The aim of these strategies is the eradication of AML cells by the immune system. In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.
Advertisement